Ferguson Wellman Capital Management Inc. Has $230,000 Holdings in Baxter International Inc. (NYSE:BAX)

Ferguson Wellman Capital Management Inc. decreased its stake in Baxter International Inc. (NYSE:BAX) by 21.3% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 6,059 shares of the medical instruments supplier’s stock after selling 1,640 shares during the period. Ferguson Wellman Capital Management Inc.’s holdings in Baxter International were worth $230,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of BAX. ARGA Investment Management LP acquired a new stake in Baxter International during the first quarter worth $10,951,000. Plimoth Trust Co. LLC acquired a new stake in shares of Baxter International during the 1st quarter valued at about $201,000. Stock Yards Bank & Trust Co. bought a new stake in Baxter International in the first quarter valued at about $204,000. Van ECK Associates Corp acquired a new position in Baxter International in the first quarter worth about $2,185,000. Finally, Argent Advisors Inc. bought a new position in Baxter International during the first quarter worth about $1,112,000. Institutional investors own 90.19% of the company’s stock.

Baxter International Stock Up 0.6 %

NYSE:BAX opened at $36.86 on Monday. The company has a market cap of $18.78 billion, a price-to-earnings ratio of 7.09, a P/E/G ratio of 1.28 and a beta of 0.59. The company has a debt-to-equity ratio of 1.35, a quick ratio of 0.91 and a current ratio of 1.40. The stock’s fifty day moving average price is $37.61 and its two-hundred day moving average price is $36.58. Baxter International Inc. has a 52-week low of $31.70 and a 52-week high of $44.01.

Baxter International (NYSE:BAX) last posted its quarterly earnings results on Tuesday, August 6th. The medical instruments supplier reported $0.68 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.66 by $0.02. The business had revenue of $3.81 billion for the quarter, compared to analysts’ expectations of $3.75 billion. Baxter International had a return on equity of 18.06% and a net margin of 16.51%. The firm’s quarterly revenue was up 2.8% compared to the same quarter last year. During the same quarter last year, the business earned $0.55 earnings per share. On average, analysts anticipate that Baxter International Inc. will post 2.96 EPS for the current year.

Analyst Ratings Changes

Several equities analysts recently commented on BAX shares. Evercore ISI cut their target price on Baxter International from $46.00 to $45.00 and set an “outperform” rating for the company in a research report on Tuesday, July 2nd. Wells Fargo & Company reduced their target price on shares of Baxter International from $44.00 to $40.00 and set an “equal weight” rating on the stock in a research note on Wednesday, August 7th. Morgan Stanley cut shares of Baxter International from an “equal weight” rating to an “underweight” rating and dropped their target price for the stock from $39.00 to $30.00 in a research report on Monday, July 15th. The Goldman Sachs Group boosted their price target on shares of Baxter International from $36.00 to $40.00 and gave the company a “neutral” rating in a research report on Thursday, August 8th. Finally, JPMorgan Chase & Co. dropped their price objective on shares of Baxter International from $44.00 to $42.00 and set a “neutral” rating for the company in a report on Wednesday, August 7th. One equities research analyst has rated the stock with a sell rating, nine have issued a hold rating and two have given a buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $42.00.

Baxter International Profile

Baxter International Inc, through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company operates through four segments: Medical Products and Therapies, Healthcare Systems and Technologies, Pharmaceuticals, and Kidney Care. The company offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; generic injectable pharmaceuticals; surgical hemostat and sealant products, advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space, including surgical video technologies, precision positioning devices, and other accessories.